Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan

BMC Urology

Research Article

Tomoaki Tanaka¹  Yujiro Nitta²  Kazuya Morimoto²  Tatsuya Nakatani²  Noriaki Nishikawa²  Satoshi Tamada²  Chikako Nishihara²  Hidenori Kawashima² 

[1] Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan;null;

关键词: Cystitis;    Pelvic Pain;    Hyperbaric Oxygen;    Interstitial Cystitis;    Bladder Capacity;   

DOI  :  10.1186/1471-2490-11-11

 received in 2010-10-02, accepted in 2011-05-24,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThere is no confirmed strategy for treating painful bladder syndrome/interstitial cystitis (PBS/IC) with unclear etiology. Therefore, a pilot study was carried out to evaluate the efficacy and safety of hyperbaric oxygen (HBO) therapy in treatment-resistant PBS/IC patients.MethodsHBO treatment (2.0 ATA for 60 minutes/day × 5 days/week for 2 or 4 weeks) was performed on 11 patients with severe symptoms that had not been improved by previous therapy regimens between December 2004 and July 2009.ResultsSeven of the 11 patients demonstrated persistent improvement in symptoms during the 12 months after HBO treatment. These responders demonstrated a decrease in the pelvic pain scale and urgency scale from 7.7 ± 1.0 and, 6.6 ± 0.9 to 3.4 ± 2.5 and 4.3 ± 2.4 after 12 months, respectively (p < 0.05). The total score of the interstitial cystitis symptom index and 24-hour urinary frequency demonstrated a significant sustained decrease from the baseline. Two responders, who received an additional course of HBO 12 and 13 months after initial treatment, respectively, did not suffer impairment for more than two years. There was one case of transient eustachian tube dysfunction and three cases of reversible exudative otitis media as a consequence of HBO treatment.ConclusionsHBO is a potent treatment for PBS/IC patients resistant to conventional therapy. It was well tolerated and provided maintained amelioration of pain, urgency and urinary frequency for at least 12 months.

【 授权许可】

CC BY   
© Tanaka et al; licensee BioMed Central Ltd. 2011